Mapi Newsletters

US, Europe, and UK Note: Additionally, pharmacy-level switching is not allowed unless it is deemed “interchangeable” by the FDA and state-level switching is allowed. Executive Summary Avastin (bevacizumab) was the…

We are very pleased that for the first time in the Newsletter’s publication to have an interview with a member of the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCePP) community. Professor Vera Ehrenstein, MPH DSc, to talk about her experience of going through the ENCePP approval process. Over the past year we have published articles about the ENCePP project’s activities and processes, but we thought what investigators and researchers would really like to know is what it would be like to go through the process themselves. And the best way to do sometimes is to ask someone who has already done so.

US, Europe, and UK Note: Additionally, pharmacy-level switching is not allowed unless it is deemed “interchangeable” by the FDA and state-level switching is allowed. Executive Summary Avastin (bevacizumab) was the…

Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (PROTECT) is a collaborative European project that comprises a programme to address limitations of current methods in the field of…

New WHO guidance on vaccine introduction FDA approves label changes for antibacterial Doribax (doripenem) describing increased risk of death for ventilator patients with pneumonia Action Plan for the Collection, Analysis,…